Skip to main content
Figure 6 | BMC Cancer

Figure 6

From: Results of multicenter double-blind placebo-controlled phase II clinical trial of Panagen preparation to evaluate its leukostimulatory activity and formation of the adaptive immune response in patients with stage II-IV breast cancer

Figure 6

Comparative analysis of cytotoxicity indices in PBMCs of patients (FAC regimen, base II) on day 21 following the third round of chemotherapy. Largely responsible for innate anticancer immunity, PBMCs retain their specific functions at the levels observed before the therapy in patients receiving Panagen throughout three courses of chemotherapy (р < 0.05). Unlike in Panagen cohort, PBMCs from placebo group patients display three-fold decrease in cytotoxicity indices by the end of the third chemotherapy course relatively to the initial level.

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us